A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function

Maximum Observed Plasma Concentration (Cmax),Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf),Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

The purpose of this study is to understand how the loss of kidney function affects study
 medicine (PF-07923568) in the body. People with some level of loss of kidney function may
 process PF-07923568 differently from healthy people. PF-07923568 is developed as a possible
 treatment for respiratory syncytial virus (RSV) infection. RSV is a common virus that affects
 the lungs and usually causes mild, cold-like symptoms. RSV can cause severe lung infections
 in infants, elderly, and adults with other serious medical conditions.
 
 This study is seeking participants who:
 
 - Have less than 25% difference in kidney function between 2 screening visits.
 
 - Meet the eGFR criteria for being assigned to groups. eGFR tells how well the kidney is
 filtering.
 
 - Are not on hemodialysis. Hemodialysis is a type of treatment that helps the body remove
 extra fluid and waste products from the blood when the kidneys are not able to.
 
 Participants will take the study medicine as capsules by mouth once at the study clinic. The
 participants will stay at the study clinic for about 5 days. During that time, the study team
 will monitor the participants. The study team will take some blood samples to test the level
 of PF-07923568. This will help us understand if some level of loss of kidney function will
 have an effect on the study medicine PF-07923568.